The bill amends sections 3902.50 and 3902.70 of the Revised Code and enacts a new section 3902.72, which prohibits drug manufacturers from engaging in certain actions regarding the acquisition and delivery of drugs to 340B covered entities. Specifically, it prevents manufacturers, repackagers, and third-party logistics providers from denying or limiting the acquisition of 340B drugs by these entities, as well as from requiring them to submit claims or utilization data as a condition for drug acquisition. The bill also establishes definitions for terms related to the 340B drug pricing program and outlines penalties for violations, including civil penalties and potential referral to the state board of pharmacy.

Additionally, the bill updates the numbering of sections, replacing the old section 3902.72 with 3902.75, and introduces new requirements for health plan issuers and pharmacy benefit managers to provide data related to drug coverage upon request. This includes eligibility information, cost-sharing details, and utilization management requirements, ensuring that such data is current and accessible in real-time. The bill aims to enhance transparency and access to necessary drug information for covered persons and their healthcare providers while ensuring compliance with federal regulations.

Statutes affected:
As Introduced: 3902.50, 3902.70, 3902.72, 3902.75